Announced Sat, 30 May · 19:21 IST

Outcome of Board meeting held on May 30, 2026

Revenue DeclineEbitda Margin CompressionExceptional ItemResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.4%1-day move
₹478.00
prior close
₹526.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-1.7-3.3-1.9+6.4+7.5+7.3+6.5+5.1+4.8+28.7+28.5
Up moveDown movePending
AI summary

Coral Laboratories Ltd's Board approved audited standalone financial results for Q4 and FY ended March 31, 2026. Revenue from operations declined to ₹8,590 Lakhs from ₹11,501 Lakhs in the previous year (25.3% decline). Profit after tax fell to ₹1,638 Lakhs from ₹2,416 Lakhs (32.2% decline), though PAT remained positive. EBITDA margin compressed from approximately 26.8% to 24%. The Board recommended a final dividend of ₹2 per share (20% on face value of ₹10). The statutory auditor issued an unmodified opinion confirming clean financial reporting. New internal auditor (M/s S K Doshi & Associates) and cost auditor (M/s Aatish Dhatrak & Associates) were appointed for FY 2026-27.

Likely market impact

The company experienced significant revenue and profit decline in FY 2025-26, though the dividend recommendation signals management confidence. The clean audit opinion and continued profitability provide some support despite the challenging year.